Milestone Pharmaceuticals Inc. announced it will release its financial results for the second quarter ending June 30, 2026, on August 12 before the market opens. The company, focused on cardiovascular medicines, will hold a conference call and webcast at 8:30am ET for investors to discuss the update. Milestone's lead product, CARDAMYST™ nasal spray, is FDA-approved for treating certain heart rhythm conditions, with ongoing development for additional uses. This earnings report will provide insights into the company's commercial progress and future outlook.
Aether Catalyst Solutions, a company focused on reducing costs and improving automotive catalytic converter catalysts, announced the appointment of Benjamin Catalano to its board of directors. Catalano brings over 30 years of experience in corporate ...
In March 2026, JPMorgan Chase launched a program allowing institutional clients to pledge Bitcoin and Ethereum as collateral for U.S. dollar loans via its Kinexys platform, with custodians like Fidelity and Coinbase holding the assets. This marks a m...
Ethereum co-founder Vitalik Buterin highlighted Bitcoin developers' work on Utreexo while outlining Ethereum's proposed hybrid scaling strategy combining UTXO-style state and dynamic state models. Ethereum researcher Toni Wahrstätter proposed native ...
Embraer has delivered a 20% total return over four months, driven by strong order growth and record aircraft deliveries. Azorra's June order pushed total E2 program orders above 500, boosting investor confidence. Additionally, three C-390 orders from...
US spot Bitcoin ETFs experienced a $389.71 million outflow last week, the largest in six weeks, reversing the previous week's $853.54 million inflow. Ethereum ETFs also saw a $2.26 million outflow, breaking a five-week streak of inflows. Despite thes...
